Antigenics, Inc.

(Public, NASDAQ:AGEN) is a buy

About: Antigenics Inc. (Antigenics), is a biotechnology company focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.

News Headlines:

Antigenics, Inc. Gets FDA Approval For Orphan Drug Designation To Oncophage For Treatment Of Glioma

Antigenics, Inc. announced that Oncophage (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma “Glioma is such an aggressive and challenging cancer that when patients are diagnosed with recurrence of this life threatening disease, they rarely live beyond six months,” said Andrew T. Parsa, MD, PhD, associate

...

Lixte Biotechnology [[LIXT.OB]] was founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to become a cancer drug discovery operation.

Lixte engages in the discovery of anti-cancer compounds to improve the treatment of malignancies with few effective treatment options, such as certain types of brain cancer. Other areas of early-stage, preclinical drug discovery include: (1) improved anti-fungal treatments for patients with compromised immunity (e.g. HIV/AIDS, bone marrow transplantation); (2) neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease; and (3) biomarker assays for diagnostic and prognostic applications in the detection of disease and monitoring of treatment effectiveness.

Since Lixte is a development-stage company which does not generate any revenue, the ability to obtain financing to fund research and drug discovery operations will be a key factor this year. The Company estimates minimum funding requirements of $750,000 for this year, which will

...

by Manuel Alvarez-Rivera, Puerto Ricobr /br /Just two years after holding a A HREF="http://globaleconomydoesmatter.blogspot.com/2007/05/iceland-2007-parliamentary-election.html"parliamentary election/A, voters in Iceland are likely to return to the polls next May 9 for an early general election. Normally, the poll would not need to be held until 2011, but these are anything but normal times in the Nordic island nation, whose economy has been devastated by the ongoing global financial crisis.br /br /With all of Iceland's three major banks under receivership since October; the national currency (the krona) having lost over half its value and the stock market over 90 percent of its value; inflation and unemployment on the rise; and the GDP expected to contract by ten percent this year, public discontent over the perceived mismanagement of the economy by the coalition government of Iceland's two major parties - the conservative Independence Party and the left-of-center Social Democratic Alliance - has fueled mounting ...

Our Director of Marketing’s Grandfather died of a massive brain tumor when she was only about a year old. His last days were a combination of comatose and automatic speaking. He recited every line that he had ever spoken on stage (he was in the entertainment industry). Although she doesn’t remember it, it was very traumatic for her family.

Recurrent Glioblastoma Multiforme is the most common type of malignant primary brain tumor in adults. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation and chemotherapy. Additionally, Brain stem cell cancer is the most lethal cancer in children, with a survival rate of less than one year after diagnosis.

NeoPharm’s agreement with NINDS will serve as another step in pursuing the validation of the company’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (“IL-13”) and its impact on possibly

...